FY25 consensus $20.88. Raises FY25 revenue view to $35B-$36B from $34.3B-$35.7B, consensus $35.34B. This guidance includes the estimated impact of implemented tariffs, but does not account for any tariffs or potential pricing actions announced or described but not implemented as well as any tariffs, sector specific tariffs, or pricing actions that could be implemented in the future.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Notable companies reporting after market close
- Is AMGN a Buy, Before Earnings?
- Amgen’s Promising Phase 3 Study on Weight Loss Drug Maridebart Cafraglutide
- Amgen’s Tarlatamab Study: A Potential Game-Changer in Lung Cancer Treatment
- Amgen’s AMG 193 Study: A Potential Game-Changer in Thoracic Tumor Treatment